Physician profile
Janet Gilbert
NPI 1386793602
$2,644.63
in general payments reported to CMS, 2019-2025
36 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $392 · 2021: $772 · 2022: $564 · 2023: $481 · 2024: $157 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $557.59 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $234.92 | 2021-2022 | |
| Abbvie INC. | $207.67 | 2020-2025 | |
| Mylan Specialty L.P. | $200.56 | 2020-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $147.39 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $144.58 | 2020-2025 | Zoryve, Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.54 | 2020-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.25 | 2020-2023 | Spiriva Respimat |
| Endo Pharmaceuticals INC. | $70.78 | 2021-2022 | |
| Astellas Pharma US INC | $70.37 | 2021-2023 | Veozah |
| Pfizer INC. | $63.80 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $56.99 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.99 | 2021 | |
| Merck Sharp & Dohme LLC | $47.02 | 2020-2023 | Belsomra |
| Corium, LLC | $45.89 | 2023 | Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.44 | 2022 | |
| Amneal Pharmaceuticals LLC | $37.31 | 2020-2021 | |
| Eisai INC. | $34.23 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $31.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $31.03 | 2021-2022 | |
| Amgen INC. | $30.95 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $30.33 | 2021 | |
| Scynexis, INC. | $29.04 | 2022 | |
| Clarus Therapeutics INC. | $24.92 | 2021 | |
| Viatris Specialty LLC | $24.13 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $21.33 | 2022 | |
| Esperion Therapeutics, INC. | $19.57 | 2024 | Nexletol |
| Allergan, INC. | $19.01 | 2020 | |
| Dermira, INC. | $15.65 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.57 | 2024 | Caplyta |
| Novo Nordisk INC | $14.61 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.82 | 2023 | Quviviq |
| Exact Sciences Corporation | $12.71 | 2023 | Cologuard Collection Kit |
| Vistapharm, INC. | $12.48 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.